Relmada Therapeutics (RLMD) Current Assets (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Current Assets data on file, last reported at $235.3 million in Q1 2026.

• On a quarterly basis, Current Assets rose 750.92% year-over-year to $235.3 million in Q1 2026; TTM through Mar 2026 was $235.3 million, a 750.92% increase from a year earlier, with the FY2025 full-year figure at $94.0 million, up 105.22% from the prior year.
• Current Assets for Q1 2026 stood at $235.3 million, up from $94.0 million in the prior quarter.
• Over the last five years, Current Assets for RLMD reached as high as $235.3 million in Q1 2026 and fell as low as $14.9 million in Q3 2025.
• Historically, Current Assets has averaged $111.5 million across 5 years, with a median of $97.5 million in 2023.
• Across the five-year window, Current Assets tumbled 73.33% in 2025 and jumped 750.92% in 2026, its largest moves.
• Year by year, Current Assets stood at $152.9 million in 2022, then slumped by 36.21% to $97.5 million in 2023, then tumbled by 53.03% to $45.8 million in 2024, then soared by 105.22% to $94.0 million in 2025, then jumped by 150.41% to $235.3 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $235.3 million in Q1 2026, $94.0 million in Q4 2025, and $14.9 million in Q3 2025.